Common Mental Disorders

On this page

Recognising Common Mental Disorders: Core Presentations

A 42-year-old woman presents to her GP describing persistent low mood, early morning wakening, and loss of interest in activities she once enjoyed. She's unsure whether she's "just stressed" or whether something more significant is wrong. This scenario exemplifies the diagnostic challenge of common mental disorders-conditions that are simultaneously prevalent, debilitating, and often under-recognised. Understanding the core features of depression , generalised anxiety disorder , and panic disorder is essential for accurate identification and timely intervention in primary care settings.

  • Depression: Characterised by persistent low mood and/or anhedonia lasting ≥2 weeks, with associated biological and cognitive symptoms

    • Lifetime prevalence: 10-15% in the UK population
    • Female:male ratio approximately 2:1
    • Peak incidence: 20-40 years, with second peak in older adults
  • Generalised Anxiety Disorder (GAD): Excessive, uncontrollable worry about multiple domains for ≥6 months

    • Prevalence: 4-7% in primary care populations
    • Chronic fluctuating course with significant functional impairment
    • Often co-occurs with depression (50-60% comorbidity)
  • Panic Disorder: Recurrent unexpected panic attacks with persistent concern about future attacks

    • Prevalence: 2-3% of general population
    • Typical onset: late adolescence to mid-30s
    • High healthcare utilisation due to physical symptom focus

📌 Mnemonic for Depression (DSM-5 criteria): SIG E CAPS
Sleep disturbance, Interest loss, Guilt/worthlessness, Energy deficit, Concentration impairment, Appetite change, Psychomotor changes, Suicidal ideation

DisorderCore FeaturesDuration ThresholdSeverity Markers
DepressionLow mood + anhedonia≥2 weeksSuicidal ideation, psychotic features, severe functional impairment
GADExcessive worry + physical tension≥6 monthsWorry >50% of days, multiple domains affected
Panic DisorderRecurrent panic attacks≥1 month of concern/behavioural changeAgoraphobic avoidance, frequency >2/week

Figure 1: Clinical photograph showing psychomotor retardation in severe depression with characteristic posture and reduced facial expression

Figure 2: Patient completing GAD-7 questionnaire showing typical scoring pattern for moderate generalised anxiety disorder

Recognising Common Mental Disorders: Core Presentations

2 - Neurobiological Underpinnings and Symptom Architecture

The monoamine hypothesis, while oversimplified, remains clinically useful for understanding antidepressant mechanisms in depression . Reduced synaptic availability of serotonin, noradrenaline, and dopamine in key neural circuits-particularly the prefrontal cortex, hippocampus, and amygdala-correlates with depressive symptoms. However, neuroplasticity changes, including reduced hippocampal neurogenesis and disrupted HPA axis regulation, better explain why antidepressants require 4-6 weeks for clinical effect despite immediate monoamine elevation.

  • Depression neurobiology:

    • HPA axis hyperactivity → sustained cortisol elevation → hippocampal volume reduction
    • Inflammatory markers (IL-6, CRP) elevated in 30-40% of cases
    • Reduced BDNF (brain-derived neurotrophic factor) impairs synaptic plasticity
  • GAD neurobiological mechanisms :

    • Amygdala hyperactivity with reduced prefrontal cortical inhibition
    • GABA-ergic system dysfunction → reduced inhibitory neurotransmission
    • Autonomic nervous system dysregulation → persistent sympathetic activation
  • Symptom cluster differentiation:

    • Depression: Anhedonia, anergia, cognitive slowing, diurnal mood variation (worse mornings)
    • GAD: Muscle tension, restlessness, concentration difficulties, sleep maintenance insomnia
    • Panic: Discrete episodes with crescendo physical symptoms peaking within 10 minutes
NeurotransmitterDepression RoleAnxiety RoleTherapeutic Target
Serotonin (5-HT)Mood, sleep, appetite regulationWorry modulation, threat processingSSRIs, SNRIs
Noradrenaline (NA)Energy, motivation, concentrationArousal, vigilanceSNRIs, TCAs
GABAReduced in severe depressionPrimary inhibitory deficit in GADBenzodiazepines (short-term)

2 — Neurobiological Underpinnings and Symptom Architecture

3 - Diagnostic Approach and Assessment Tools

A 28-year-old man presents with palpitations, chest tightness, and fear of dying. He's attended A&E three times in the past month with normal ECGs and troponins. This presentation pattern-recurrent physical symptoms with negative investigations-should trigger consideration of panic disorder . NICE NG222 recommends structured assessment tools to standardise diagnosis and monitor treatment response in primary care.

  • Validated screening instruments:

    • PHQ-9 (Patient Health Questionnaire-9): Depression severity scoring
      • Score 0-4: minimal; 5-9: mild; 10-14: moderate; 15-19: moderately severe; ≥20: severe
      • Question 9 (suicidal ideation) requires immediate risk assessment regardless of total score
    • GAD-7: Anxiety severity scoring
      • Score ≥10: probable GAD requiring clinical interview
      • Sensitivity 89%, specificity 82% at threshold ≥10
    • Panic Disorder Severity Scale: Frequency, distress, and avoidance measurement
  • Diagnostic hierarchy considerations:

    • Rule out organic causes: thyroid dysfunction (TSH), anaemia (FBC), B12/folate deficiency
    • Medication review: β-agonists, corticosteroids, stimulants can mimic anxiety
    • Substance use: alcohol withdrawal, caffeine excess, cannabis use
  • Red flags requiring urgent psychiatric assessment 🚩:

    • Active suicidal planning with intent and means
    • Psychotic symptoms (delusions, hallucinations)
    • Severe self-neglect or catatonic features
    • Acute risk to others
Assessment ToolScore RangeClinical Action ThresholdMonitoring Frequency
PHQ-90-27≥10: Consider treatmentEvery 2-4 weeks during active treatment
GAD-70-21≥8: Probable anxiety disorderEvery 4 weeks initially
Columbia Suicide Severity Rating ScaleN/AAny ideation with plan/intentEvery contact if risk identified

Figure 3: PHQ-9 depression screening questionnaire with scoring guide showing moderate depression pattern

3 — Diagnostic Approach and Assessment Tools

4 - Differential Diagnosis and Discriminating Features

Distinguishing between depression and GAD presents a common clinical challenge, particularly given their 50-60% comorbidity rate. The key discriminator lies not in the presence of worry-which occurs in both-but in its quality and associated features. In depression, worry is typically past-focused, ruminative, and centred on themes of failure or worthlessness. In GAD, worry is future-oriented, uncontrollable, and spans multiple domains (health, finances, relationships, work).

  • Depression vs GAD key differentiators:

    • Anhedonia: Core feature of depression, may be absent in pure GAD
    • Worry quality: Ruminative (depression) vs anticipatory (GAD)
    • Physical symptoms: Fatigue and psychomotor changes predominate in depression; muscle tension and restlessness in GAD
    • Temporal pattern: Diurnal variation common in depression (worse mornings); GAD symptoms persist throughout day
  • Panic disorder vs cardiac disease :

    • Age <40, multiple negative investigations, symptom onset at rest (not exertion) favour panic
    • Panic attacks peak within 10 minutes; cardiac ischaemia typically builds gradually
    • Derealization/depersonalization strongly suggest panic rather than cardiac aetiology
  • Bipolar disorder screening in apparent depression:

    • MDQ (Mood Disorder Questionnaire) if history suggests manic/hypomanic episodes
    • Red flags: Family history, early onset (<25 years), antidepressant-induced activation
    • NICE CG185: Consider bipolar if ≥2 previous depressive episodes or atypical features
FeatureDepressionGADPanic Disorder
Core emotionSadness, emptinessApprehension, tensionAcute terror
Cognitive focusPast failures, guiltFuture threatsImmediate catastrophe
Physical symptomsFatigue, appetite/sleep changeMuscle tension, restlessnessDiscrete episodes: palpitations, breathlessness
Time coursePersistent (weeks-months)Chronic fluctuating (months-years)Episodic (minutes-hours)
Response to reassuranceMinimalTemporaryBrief

Clinical Pearl: If a patient describes worry as "stuck on a loop" they can't stop despite recognizing it's excessive, think GAD. If they describe feeling "empty" or "nothing matters anymore," think depression.

4 — Differential Diagnosis and Discriminating Features

5 - Evidence-Based Treatment Pathways

NICE NG222 advocates a stepped-care approach for depression and anxiety disorders , matching intervention intensity to severity and treatment response. For mild depression (PHQ-9 10-15), initial management should include psychoeducation, sleep hygiene, and structured physical activity (150 minutes moderate-intensity exercise weekly), with watchful waiting for 2 weeks before escalating. Moderate-to-severe depression (PHQ-9 ≥16) warrants first-line pharmacological or high-intensity psychological intervention.

  • First-line antidepressant therapy:

    • SSRIs preferred: Sertraline 50mg OD (cardiac safety profile) or citalopram 20mg OD
    • Titrate at 2-4 week intervals based on tolerability and response
    • Continue for ≥6 months after remission (first episode); ≥2 years if recurrent
    • Monitor: Suicidal ideation (especially weeks 1-4), GI side effects, sexual dysfunction
  • GAD pharmacological management:

    • First-line: Sertraline 50mg OD or escitalopram 10mg OD
    • Alternative if SSRIs ineffective/not tolerated: SNRI (venlafaxine XL 75mg OD) or pregabalin 150mg daily in divided doses
    • Avoid benzodiazepines beyond 2-4 weeks (dependence risk, cognitive impairment)
  • Panic disorder specific considerations:

    • SSRIs effective for both panic frequency and anticipatory anxiety
    • Start low (e.g., sertraline 25mg) due to initial activation/jitteriness
    • CBT with exposure therapy superior to medication alone for agoraphobic avoidance
  • When to escalate care:

    • No response after 2 adequate antidepressant trials (adequate = correct dose × 6-8 weeks)
    • Severe functional impairment despite treatment
    • Psychotic features, high suicide risk, or severe self-neglect
MedicationStarting DoseTarget DoseKey MonitoringCommon Adverse Effects
Sertraline50mg OD100-200mg ODSuicidal ideation, GI symptomsNausea, diarrhoea, sexual dysfunction
Citalopram20mg OD20-40mg OD (max 40mg)QTc if cardiac risk factorsDrowsiness, sexual dysfunction
Venlafaxine XL75mg OD150-225mg ODBP (dose-dependent ↑)Nausea, sweating, withdrawal if stopped abruptly
Mirtazapine15mg nocte30-45mg nocteWeight, sedationWeight gain, sedation (paradoxically less at higher doses)

5 — Evidence-Based Treatment Pathways

6 - Complex Cases and Treatment-Resistant Scenarios

A 55-year-old woman with depression has tried three SSRIs sequentially without significant improvement. She has comorbid type 2 diabetes, takes metformin and atorvastatin, and describes her mood as "flat" with profound fatigue. This scenario requires synthesis of multiple factors: treatment resistance definition (failure of ≥2 adequate trials), medical comorbidity impact, and potential need for specialist intervention. NICE NG222 recommends considering augmentation strategies or switching to different mechanistic classes before labelling true treatment resistance.

  • Defining inadequate response:

    • <50% reduction in PHQ-9 score after 6-8 weeks at therapeutic dose
    • Persistent functional impairment despite symptom improvement
    • Intolerable adverse effects preventing dose optimization
  • Augmentation strategies for depression:

    • Add mirtazapine to SSRI (complementary mechanisms, "California rocket fuel")
    • Lithium augmentation (specialist initiation): requires plasma monitoring (target 0.4-0.8 mmol/L)
    • Antipsychotic augmentation (e.g., aripiprazole 5-10mg): evidence in severe/psychotic depression
  • Special population considerations:

    • Pregnancy: Sertraline preferred SSRI; avoid paroxetine (cardiac malformation risk)
    • Elderly: Start doses 50% lower; monitor falls risk, hyponatraemia (SIADH)
    • Renal impairment: Dose-reduce citalopram/escitalopram; sertraline safer
  • GAD treatment resistance :

    • If 2 SSRIs ineffective, consider SNRI or pregabalin
    • CBT essential component-medication alone insufficient for long-term remission
    • Mindfulness-based cognitive therapy effective for relapse prevention
Clinical ScenarioAdjustment StrategyEvidence LevelMonitoring Requirements
SSRI partial responseAdd mirtazapine 15-30mg nocteModerate (RCT evidence)Weight, lipids, sedation
SSRI + SNRI failureSwitch to mirtazapine monotherapyModerateAs above
Severe/psychotic depressionAdd antipsychotic (e.g., olanzapine 5-10mg)Strong (NICE recommended)Metabolic parameters, EPS
Chronic GAD with panicCombine SSRI + CBT with exposureStrongAdherence to exposure tasks

🚩 Red Flag: Sudden improvement in mood after prolonged severe depression may indicate suicide planning (patient has made decision, feels relief). Requires immediate risk reassessment.

6 — Complex Cases and Treatment-Resistant Scenarios

High Yield Summary

Key Take-Aways:

  • Depression requires ≥2 weeks of low mood/anhedonia plus ≥5 additional symptoms; PHQ-9 ≥10 indicates moderate severity warranting active treatment
  • GAD involves excessive worry across multiple domains for ≥6 months; GAD-7 ≥10 has 89% sensitivity for diagnosis
  • Panic disorder features recurrent unexpected panic attacks peaking within 10 minutes, with ≥1 month of persistent concern or behavioural change
  • First-line pharmacotherapy for all three conditions: SSRIs (sertraline 50-200mg or citalopram 20-40mg daily)
  • Adequate treatment trial = therapeutic dose × 6-8 weeks; <50% symptom reduction defines inadequate response
  • NICE NG222 stepped-care: mild disease → guided self-help; moderate → SSRI or CBT; severe → combination therapy
  • Treatment duration: ≥6 months post-remission (first episode), ≥2 years (recurrent depression)

Essential Common Mental Disorders Numbers:

MetricValueClinical Significance
PHQ-9 treatment threshold≥10Moderate depression requiring intervention
GAD-7 diagnostic threshold≥10Probable GAD (89% sensitivity)
SSRI therapeutic window6-8 weeksMinimum trial duration before switching
Depression continuation6-12 monthsPost-remission to prevent relapse
Panic attack peak<10 minutesDiscriminates from sustained anxiety

Key Principles/Pearls:

  • Always screen for bipolar disorder before starting antidepressants in young patients (<25) or those with family history-antidepressant monotherapy can precipitate mania
  • Suicidal ideation may transiently increase in first 2-4 weeks of SSRI treatment, particularly in patients <25 years-requires close monitoring
  • Benzodiazepines provide rapid symptom relief but cause dependence within 2-4 weeks; reserve for acute crisis only, never as maintenance therapy
  • Sexual dysfunction affects 40-60% of SSRI users; proactively discuss and consider switching to mirtazapine or bupropion if problematic
  • Abrupt SSRI discontinuation causes withdrawal syndrome (dizziness, paraesthesia, flu-like symptoms); taper over ≥4 weeks

Quick Reference:

ScenarioFirst ActionEscalation Trigger
PHQ-9 10-15 (mild-moderate)Guided self-help or SSRINo improvement 6-8 weeks
PHQ-9 ≥20 (severe)SSRI + high-intensity CBTSuicidal ideation, psychosis, self-neglect
GAD-7 ≥10SSRI (sertraline 50mg)Failure of 2 SSRIs at therapeutic doses
Recurrent panic attacksSSRI (start low: 25mg sertraline) + CBTAgoraphobic avoidance developing
Treatment resistanceSwitch class or augment (mirtazapine/lithium)Consider specialist referral after 3 failed trials

Practice Questions: Common Mental Disorders

Test your understanding with these related questions

A 27-year-old woman presents with amenorrhea, weight loss, and excessive exercise. Her BMI is 16 kg/m². She has bradycardia and hypotension. What is the most serious immediate risk?

1 of 5

Flashcards: Common Mental Disorders

1/10

What is the pharmacological management of PTSD? _____ or SSRI

TAP TO REVEAL ANSWER

What is the pharmacological management of PTSD? _____ or SSRI

Venlafaxine (SNRI)

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial